Pharmaceuticals & Healthcare

Positioning Ireland as a global innovation leader in the 4th Industrial Revolution

Posted by:

Professor Pugatch delivered a keynote presentation at the 25th Annual Conference of the Irish Pharmaceutical Healthcare Association (IPHA) at Dublin, Ireland, themed ‘Patient Care, Powered By Innovation’.

In the field of professional boxing, Ireland was and remains a global superpower and a role model. Yet in the field of biopharmaceutical innovation, Ireland does not step into the ring of greats:

  • Despite retaining the reputation of a global leader in advances biopharmaceutical manufacturing – with €10 billion invested over the past decade – ...
Continue Reading →
0

New Pugatch Consilium Study Shows How Countries Can Develop Biotech Industry

Posted by:

A Pugatch Consilium study released today commissioned by the Biotechnology Innovation Organization (BIO) highlights strategies, policies and best practices that have been successful in creating an environment in which biotechnology innovation can flourish around the world.

The fifth edition of the Building the Bioeconomy report shows the correlation between economies with pro-innovation policy frameworks and those achieving strong biotechnology outputs. By examining 28 different indicators ranging from public policy inputs to biotechnology outputs, the report provides a full and detailed ...

Continue Reading →
0

Daniel Coriat Sharing the Results of the BCI 2017 | Hosted by the CIF

Posted by:

In Santiago de Chile, Daniel Coriat shared the results of the BCI 2017 with a distinguished audience at an event hosted by CIF, the local Chilean pharmaceutical trade association.  During the event, representatives of the Ministry of Economy and the Ministry of Foreign Affairs highlighted the importance that the BCI tool provides as empirical evidence of the effects of public policy.  Here Dan is being interviewed by a renowned journalist in Chile about the BCI:

http://www.infinita.cl/entrevistas/2018/05/09/daniel-coriat-director-consultora-pugatch-consilium

Continue Reading →
0

Is Taiwan Ready for the Top Spot?

Posted by:

Professor Meir Pugatch spoke today at the forum “Positioning Taiwan as an Asia-Pacific Biomedical R&D Hub” which took place the International Convention Center in Taipei, and included the Vice President of Taiwan and additional government officials.

Professor Pugatch presented a comprehensive analysis of Taiwan’s competitiveness in the biotech sector, as well as recent improvements to and remaining challenges in Taiwan’s path to leadership in global biotech innovation.

By utilizing a competitive mentality that views policy as instrumental in achieving economic and societal ...

Continue Reading →
0

Towards a Sustainable European Market for Off-Patent Biologics

Posted by:

Professor Meir Pugatch spoke yesterday at the event: “Building a sustainable Policy Framework for Biologics and Biosimilar Medicines in Europe”, which took place at the European Parliament, and included members from the European Commission and organizations such as Medicines for Europe, ESMO and EPF. Professor Pugatch presented the findings of a new study by Pugatch Consilium, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

With 38 biosimilar medicines approved and marketed and hundreds of clinical trials on ...

Continue Reading →
0

BCI 2017 Latin America Report and Results Released

Posted by:

Pugatch Consilium unveiled at the Financial Times Latin America Healthcare & Life Sciences Summit in Sao Paulo Brazil the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Latin America Special Report. This Report is derived from the main 2017 BCI Survey, a global executive opinion survey and index that measures the relative attractiveness of economies to investment from biopharmaceutical research-based companies.

The Report deep-dives into ten Latin American countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Mexico, Panama and Peru. ...

Continue Reading →
0

Debunking the IP and Access to Medicines Myth Once and For All

Posted by:

Pugatch Consilium is today releasing the report Unlocking Global Health Strengthening Availability of Essential Medicines by Enhancing Healthcare Financing and Reducing Supply Chain Costs.

This report examines a common misperception in the international community: that patents and IP incentives block access to medicines.

 

An age-old debate: Patents and access

Discussions over the impact – positive or negative; rarely neutral – that IP rights have had and continue to have on the creation and dissemination of new ideas and commercial products is ...

Continue Reading →
0

To SPC or not to SPC…

Posted by:

Does the EU Commission really think weakening IP incentives for biopharmaceutical innovation in Europe is going to create more jobs and economic activity?

by Dr David Torstensson, Partner, Pugatch Consilium

As an industry the research-based biopharmaceutical sector is one of Europe’s biggest success stories. Companies like Novartis, Roche, Sanofi Aventis, Novo Nordisk, AstraZeneca and GSK are some of the largest, most innovative and successful research-based biopharmaceutical companies in the world. Not only do these companies have a long track record of producing ...

Continue Reading →
0

BCI 2017 Report and Results Released

Posted by:

Pugatch Consilium has released the 2017 Biopharmaceutical Competitiveness & Investment (BCI) Survey. An executive opinion survey, in 2017 the BCI polled business leaders and local general managers from the biopharmaceutical industry about the investment environment in 31 markets. The results are available in the linked report below.

 

The headline results of the 2017 BCI Survey include:

 

  • The policy environment matters a great deal for biopharmaceutical investment decisions. Economies with policies supporting biopharmaceutical innovation and investment are much more likely to actually secure ...
Continue Reading →
0

Preliminary BCI 2017 Results and New Impact Analysis Published

Posted by:

In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the annual Biopharmaceutical Competitiveness & Investment (BCI) Survey, previewed at the International BIO Convention in San Diego in June, reveal that biopharmaceutical competitiveness turns on the policy conditions that countries decide to put in place.

 

A new blog post by Prof Meir Pugatch on PhRMA’s The Catalyst discusses these results and ...

Continue Reading →
0
Page 1 of 5 12345